ResearchPUBMEDMar 26
Scientists studying a rare childhood cancer called alveolar rhabdomyosarcoma have discovered how cancer cells make extra copies of certain genes that help them grow. They found that different parts of chromosomes (the structures that hold our genes) get copied in different ways—some amplify just one gene, while others amplify multiple genes at once. Understanding these patterns helps doctors figure out which patients might need different treatments.
WHY IT MATTERSThis research identifies specific genetic changes in rhabdomyosarcoma that could lead to targeted treatments tailored to each patient's tumor genetics, potentially improving survival rates for children with this aggressive cancer.
ResearchPUBMEDMar 26
Scientists are using a new technology called long-read sequencing that can read much longer pieces of DNA than older methods. This helps doctors find genetic causes of rare diseases that were previously missed, especially when mutations hide in repetitive parts of the genome or involve large structural changes. The technology is becoming an important tool in genetic testing labs worldwide.
WHY IT MATTERSIf you have a rare genetic disease that wasn't diagnosed by standard genetic testing, long-read sequencing may finally identify the genetic cause—potentially opening doors to targeted treatments and genetic counseling for your family.
PolicyPUBMEDMar 26
Scientists and doctors are saying that the system for developing and selling medicines for rare diseases needs improvement. New discoveries in genetics have helped create targeted treatments, but these medicines are often very expensive and hard to access. The article calls on researchers, doctors, and other groups to work together to make rare disease medicines more affordable and available to patients who need them.
WHY IT MATTERSIf you or a loved one has a rare disease, this research highlights why medicines for your condition may be expensive or hard to get — and pushes for systemic changes that could improve your access to treatment options.
NewsPUBMEDMar 26
Leishmaniasis is a rare disease caused by tiny parasites that can affect the skin, mouth, and nose. This article describes an unusual case where a patient developed leishmaniasis that ate through the wall between their nostrils (nasal septum). Doctors from different specialties—ear/nose/throat, infectious diseases, and tropical medicine—had to work together to diagnose and treat this rare form of the disease.
WHY IT MATTERSIf you have unexplained nasal sores, perforations, or mouth ulcers combined with skin lesions—especially after travel to Central/South America or the Mediterranean—leishmaniasis should be considered and requires coordinated care across multiple medical specialties.
ResearchPUBMEDMar 26
Researchers are developing a new way to make sure patients with Aicardi-Goutieres Syndrome (AGS) have a real voice in designing clinical trials for new treatments. AGS is a rare genetic disease that affects the brain and causes inflammation. This study creates a method to listen to what matters most to patients and families so that future drug trials measure the things that actually improve their lives.
WHY IT MATTERSAs new treatments for AGS move toward clinical trials, this research ensures that the outcomes being measured in those trials reflect what patients and families actually care about—not just what doctors think is important.
ResearchPUBMEDMar 26
Scientists studied a large group of patients in Europe with rare diseases caused by problems in mitochondrial aminoacyl-tRNA synthetases—proteins that help mitochondria (the energy centers of cells) make other proteins. They found 38 patients with 63 different genetic changes and created a method to match patients' symptoms with similar cases in medical literature, which helps doctors figure out what disease a patient actually has.
WHY IT MATTERSIf you or your child has unexplained seizures, developmental delays, or neurological symptoms, this research provides doctors with a new tool to identify whether mitochondrial aminoacyl-tRNA synthetase variants are the cause—potentially leading to a diagnosis after years of testing.
ResearchPUBMEDMar 26
Researchers tested new ways to help more diverse groups of people join rare disease genetic studies. They used strategies like having doctors refer patients, providing language support, and bringing blood tests to people's homes. About 83% of people they tried to recruit successfully joined the study, showing these methods work well.
WHY IT MATTERSIf you or your family member has a rare disease and belongs to a group that has been underrepresented in genetic research, this work means future studies are more likely to actively recruit and support your participation, potentially leading to better understanding of your condition.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new gene therapy called SGT-212 for Friedreich's ataxia, a rare disease that affects how the body moves and coordinates. This is the first time this treatment is being tested in humans. The study will enroll 10 patients and follow them for about 5 years to see if the treatment is safe and works well.
WHY IT MATTERSThis is the first human trial of SGT-212 for Friedreich's ataxia, offering eligible patients access to a potentially disease-modifying gene therapy that addresses the underlying genetic cause rather than just managing symptoms.
Clinical trialCLINICALTRIALSMar 26
Researchers are looking for 1,500 people with inherited eye diseases caused by rare genetic changes to join a study. The study has two parts: first, they'll collect genetic information and eye health data from participants, and second, they'll follow some participants over time to understand how these eye diseases progress. This international study is now accepting new participants.
WHY IT MATTERSIf you have an inherited retinal disease with a rare genetic variant, enrolling in this registry could help researchers understand your condition better and speed up development of future treatments while contributing to a global database of genetic information.
Clinical trialCLINICALTRIALSMar 26
Researchers at Emory University are testing a new combination of medicines for children whose cancer has come back or stopped responding to previous treatments. The study combines three drugs: sirolimus (which slows cell growth), celecoxib (an anti-inflammatory), and two chemotherapy drugs given in low doses. The goal is to see if this combination works better than standard treatments for solid tumors and brain cancers in children.
WHY IT MATTERSThis trial offers a potential new treatment option for children with recurrent or refractory cancers who have limited alternatives, though enrollment is currently closed.
ResearchCLINICALTRIALSMar 26
Researchers completed a study testing whether an artificial intelligence tool can help regular doctors better diagnose skin conditions. The AI was designed to reduce mistakes and unnecessary specialist referrals by giving primary care doctors better information about skin problems like melanoma, psoriasis, and other conditions. With only 9 participants, this was a small early-stage study to see if the technology works.
WHY IT MATTERSIf this AI tool works well, patients with rare skin conditions like hidradenitis suppurativa could get faster, more accurate diagnoses from their regular doctor instead of waiting for specialist appointments.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new treatment for calciphylaxis, a serious condition where calcium builds up in blood vessels and skin tissue, causing painful sores. The treatment uses special cells from amniotic fluid (the fluid around a baby during pregnancy) to see if they can help heal the damage. This is an early-stage trial with a small group of 9 patients to check if the treatment is safe and works.
WHY IT MATTERSCalciphylaxis has very few treatment options and high mortality rates — this trial offers patients with chronic kidney disease a chance to access an experimental stem cell therapy that could reduce tissue damage and improve survival.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a combination of two immunotherapy drugs in patients with four types of rare cancers: neuroendocrine tumors, biliary tract cancers, ovarian clear cell carcinoma, and tumors with high microsatellite instability. This Phase 2 trial involves 240 patients and is based on earlier research showing these cancers may respond well to this type of treatment.
WHY IT MATTERSPatients with these rare cancers now have access to a targeted immunotherapy combination that showed promise in earlier studies, potentially offering a new treatment option for cancers that historically have limited therapeutic choices.
ResearchCLINICALTRIALSMar 26
Researchers in Italy completed a registry study where they collected information from 82 patients with Angelman Syndrome. A registry is like a database that stores health information to help doctors and scientists learn more about a disease. No patients received any experimental treatment—they just shared their medical information, which is kept private and secure.
WHY IT MATTERSThis completed Italian registry provides real-world data on Angelman Syndrome patients that researchers can use to design better treatments and understand how the condition affects people over time.
Clinical trialCLINICALTRIALSMar 26
Researchers are looking for pregnant women and breastfeeding mothers who have taken or are taking a medication called odevixibat to join a safety study. The study will track the health of these women and their babies to make sure the medication is safe to use during pregnancy and while breastfeeding. About 20 people will participate, and doctors will collect information from the mothers, babies, and healthcare providers involved in their care.
WHY IT MATTERSThis surveillance program is recruiting pregnant and lactating women exposed to odevixibat to establish safety data for a medication used in rare bile acid disorders, filling a critical gap in pregnancy and lactation safety information.
ResearchCLINICALTRIALSMar 26
Researchers completed a study testing whether an AI tool called Legit.Health Plus can help doctors better diagnose rare and complicated skin conditions. The tool was tested with 15 healthcare providers to see if it could reduce the gap between what general doctors and skin specialists diagnose. This matters because conditions like Generalized Pustular Psoriasis and Hidradenitis Suppurativa can be missed or misdiagnosed, delaying proper treatment.
WHY IT MATTERSThis completed trial tested an AI diagnostic tool specifically designed to help primary care doctors accurately identify rare skin conditions like Generalized Pustular Psoriasis and Hidradenitis Suppurativa, which are often missed in non-specialist settings.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new cancer treatment called CART19 for children and young adults with specific types of blood cancer (B-ALL). The treatment uses the patient's own immune cells that are modified in a lab to fight cancer cells. This trial is looking for patients with rare, high-risk forms of this cancer, including some cases that have come back after previous treatment.
WHY IT MATTERSThis trial is actively recruiting children and young adults with hard-to-treat B-ALL subtypes (hypodiploid, t(17;19), KMT2A, and CNS relapse cases) — these patients have limited treatment options and this study offers access to an advanced cell therapy approach.
ResearchCLINICALTRIALSMar 26
Researchers in Pakistan completed a study testing whether a mindfulness program called MindUP could help orphan teenagers feel less depressed, anxious, and stressed. The program teaches techniques to calm the mind and manage difficult emotions. This study involved 61 teenagers living in orphan care institutions who often experience sadness and worry from losing their parents and living in institutional settings.
WHY IT MATTERSThis research demonstrates that mindfulness-based interventions can be effective mental health tools for vulnerable adolescent populations in resource-limited settings, potentially offering low-cost psychological support for orphaned youth.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new cancer drug called CLR 131 in children and young adults whose cancers have come back or stopped responding to standard treatments. The study includes kids with several types of hard-to-treat cancers like neuroblastoma, sarcomas, and brain tumors. This is an early-stage study to figure out the right dose and see if the drug is safe and effective.
WHY IT MATTERSThis trial offers a potential treatment option for children with relapsed or refractory neuroblastoma, sarcomas, and other pediatric solid tumors where standard treatments have failed—conditions with very limited curative options.
ResearchCLINICALTRIALSMar 26
Researchers at a hospital in France are collecting biological samples (like blood) from 1,000 patients with rare nervous system diseases that may be caused by the immune system attacking the body. These samples will help scientists find new ways to diagnose and treat these diseases by identifying special markers in the blood that show disease activity.
WHY IT MATTERSIf you have a rare autoimmune neurological disease, participating in this sample collection could help researchers discover new biomarkers and treatments specifically for conditions like yours.